A surge of innovation in next-generation drugs for diabetes treatment is reshaping therapeutic strategies by targeting novel metabolic pathways. Beyond conventional insulin and oral hypoglycemics, recent developments include dual and triple agonists that simultaneously modulate multiple hormonal pathways, such as GLP-1/GIP receptor agonists. Sodium-glucose co-transporter inhibitors (SGLT1/SGLT2) continue to gain traction due to their cardiovascular and renal protective effects. Additionally, small-molecule insulin mimetics and gene-editing techniques are opening new avenues for disease-modifying treatments. Personalized medicine approaches and advancements in drug delivery systems, including smart insulin and implantable devices, are enhancing efficacy while minimizing side effects. These breakthroughs offer promising prospects for achieving sustained glycemic control and preventing diabetes-related complications.
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Diabetes reduction (pre diabetes and type 2) with integrative medicine
F Buck Willis, Christian College of Medicine, Belize
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : AI receptor binding studies reveal GPR146 conformational states across diabetic phenotypes: Analysis of C peptide and insulin interactions in cholesterol metabolism cortisol regulation and the vitamin D renin angiotensin axis
David Petch, utR Biotech, Canada
Title : Comparative outcomes of antihypertensive therapy in black vs non hispanic white patients with hypertension and cardiovascular disease
Anil Harrison, Midwestern University, United States